-

01:04:34 AM

CDNA Stock News

CDNA - Caredx Inc

01/20/22 7:00 AM

Nasdaq : CDNA

CareDx Joins Forces with MOTTEP to Increase Organ Donations for Minority Transplant Patients and Support High-Risk, Underserved Communities

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced

RHEA-AI

neutral

01/12/22 7:00 AM

Nasdaq : CDNA

Landmark ADMIRAL Study Publication with CareDx’s AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance

CareDx, Inc. (Nasdaq:

RHEA-AI

neutral

01/11/22 7:00 AM

Nasdaq : CDNA

partnershipclinical trial

CareDx Partners with Multiple Biotechnology Companies to Use AlloCell in CAR T-Cell Therapy Clinical Studies

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and

RHEA-AI

neutral

01/10/22 7:00 AM

Nasdaq : CDNA

CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2021

The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for

RHEA-AI

very positive

01/07/22 7:00 AM

Nasdaq : CDNA

NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

CareDx, Inc. (Nasdaq: CDNA) – The Transplant

RHEA-AI

negative

01/06/22 7:00 AM

Nasdaq : CDNA

CareDx Successfully Completes CLIA Validation of AlloMap Kidney in Preparation for Commercial Launch

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery,

RHEA-AI

neutral

01/05/22 7:00 AM

Nasdaq : CDNA

acquisition

CareDx Expands Its Medication Adherence Services with the Acquisition of The Transplant Pharmacy

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically

RHEA-AI

very positive

01/04/22 7:00 AM

Nasdaq : CDNA

partnership

CareDx Partners with ISHLT in a Transplant Innovation Research Grant to Improve Outcomes for Heart and Lung Transplant Patients

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery,

RHEA-AI

neutral

12/16/21 7:00 AM

Nasdaq : CDNA

CareDx Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development, and commercialization of

RHEA-AI

neutral

12/13/21 7:00 AM

Nasdaq : CDNA

partnership

CareDx Partners with the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Organization in Launching Prospective, Multi-Center Pediatric Kidney Transplant Study

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company focused on the discovery, development and

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

CDNA Data:

IndustryMedical Laboratories
Websitewww.caredx.com
CeoPeter Maag
Security nameCaredx Inc
Issue typecs
SectorHealth Care and Social Assistance
Sic code8071
Employees466
Tags
- Health Technology
- Medical Specialties
- Health Care and Social Assistance
- Medical Laboratories
Address1 Tower Place
Address29Th Floor
StateCalifornia
CitySouth San Francisco
Zip94080
CountryUS
Phone14152872300

CDNA Description:

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.